First study to monitor COVID-19 vaccine-induced immune responses in Africa
Yemaachi Biotech’s Heritage Study is the first of its kind to compare immune responses to the same vaccine in both African and European populations, and could provide important insights into how vaccines can be optimally designed for African people
Yemaachi Launches Sheba HPV Test for screening of high risk HPV variants that cause cervical cancer
Yemaachi marks cervical cancer awareness month with the launch of the Sheba HPV Test, a cervical cancer screening tool that features at-home sampling and high risk HPV DNA detection.
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.
H3D Partners with Yemaachi to Utilise African Genetic Diversity to Develop New Tools for Improving Treatment Outcomes for the African Patient Populations
The Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT) has entered into a strategic partnership with Yemaachi Biotech, to exploit African genetic diversity by identifying new therapies and platforms that optimize cancer treatments for African patient populations.